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ORIGINAL ARTICLE
Early improvement in food cravings are associated with long-
term weight loss success in a large clinical sample
M Dalton1, G Finlayson1, B Walsh2, AE Halseth2, C Duarte3 and JE Blundell1
BACKGROUND: Food cravings are associated with dysregulated eating behaviour and obesity, and may impede successful
weight loss attempts. Gaining control over food craving is therefore a component in the management of obesity. The current paper
examined whether early changes in control over food craving (assessed using the Craving Control subscale on the Control of Eating
Questionnaire (CoEQ)) was predictive of weight loss in four phase 3 clinical trials investigating a sustained-release combination of
naltrexone/bupropion (NB) in obese adults. The underlying component structure of the CoEQ was also examined.
METHOD: In an integrated analysis of four 56-week phase 3 clinical trials, subjects completed the CoEQ and had their body weight
measured at baseline and at weeks 8, 16, 28 and 56. All analyses were conducted on subjects who had complete weight and CoEQ
measurements at baseline and week 56, and had completed 56 weeks of NB (n= 1310) or placebo (n= 736). A latent growth curve
model was used to examine whether early changes in the CoEQ subscales were associated with decreases in weight loss over time.
Confirmatory factor analysis (CFA) was used to determine the psychometric properties of the CoEQ.
RESULTS: The factor structure of the CoEQ was consistent with previous findings with a four-factor solution being confirmed:
Craving Control, Positive Mood, Craving for Sweet and Craving for Savoury with good internal consistency (Cronbach’s α= 0.72–
0.92). Subjects with the greatest improvement in Craving Control at week 8 exhibited a greater weight loss at week 56.
CONCLUSIONS: These findings highlight the importance of the experience of food cravings in the treatment of obesity and
support the use of the CoEQ as a psychometric tool for the measurement of food cravings in research and the pharmacological
management of obesity.
International Journal of Obesity advance online publication, 2 May 2017; doi:10.1038/ijo.2017.89
INTRODUCTION
Food craving is defined as the intense desire to eat a particular
food and is thought to be distinct from hunger in that food
cravings occur spontaneously, whereas hunger increases in
intensity over time spent without food. The experience of food
craving is a relatively common phenomenon;1,2 however, the
intensity of food craving varies greatly among individuals. More
frequent and intense food cravings are associated with loss of
control over eating and poor weight management. For example,
research has shown that increased food craving is related to
higher body mass index (BMI)3–5 and a greater tendency toward
binge eating, emotional and external eating.6–9 Therefore, food
craving can be seen as existing on a continuum of experience,
ranging from mild to extreme,10 is present in normal and
disordered eating patterns, and may be elicited under a number
of conditions.
Research suggests that reducing and managing food cravings is
a key component in the management of obesity and successful
weight loss maintenance.11,12 For example, in one weight loss
intervention trial that targeted overweight/obese individuals with
impaired glucose tolerance, greater food cravings at baseline were
associated with a higher BMI, more frequent weight loss attempts,
greater weight cycling and increased feelings of perceived
deprivation whilst dieting.5,13 It is important to note that, in this
study, baseline food craving did not predict weight loss success at
the end of the intervention. However, the authors did not report
the change in the frequency or intensity of food cravings
experienced across the intervention. Therefore, whilst food
craving and increased desire to eat ‘forbidden’ foods may
contribute to poor compliance and adherence with weight loss
interventions, early changes in food craving may be a good clinical
indicator of weight loss success and the reduction of food craving
represents an important aim of antiobesity therapy.
Sustained-release naltrexone/bupropion (NB; Contrave in the
United States and Msyimba in the European Union) is indicated as
an adjunct to reduced-calorie diets and increased physical activity
for weight loss and chronic weight management in obese adults
or those who are overweight with at least one obesity-related
comorbidity. NB is believed to act via two distinct mechanisms
that contribute to weight loss. The first relates to appetite
suppression through bupropion-mediated stimulation of pro-
opiomelanocortin neurons in the hypothalamus and naltrexone-
mediated suppression of the autoinhibitory pathways of the same
pro-opiomelanocortin neurons. The second is via the regulation of
the mesolimbic dopaminergic pathways to reduce food cravings
and enhance the control of eating behaviour.14,15
The primary aim of the current paper was to determine whether
early changes in self-reported control over food craving (i.e.
Craving Control) was associated with weight loss outcomes by
examining those who exhibit early improvements in Craving
Control (‘responders’) compared with those who do not exhibit
early improvements in Craving Control (‘non-responders’) in a
combined analysis of four 56-week phase 3 clinical trials designed
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to examine the effect of treatment with NB on weight loss in
overweight/obese adults. The pharmacological treatment out-
comes of these clinical trials have been reviewed and published
elsewhere.14,16–19 Food craving was assessed using the validated
Control of Eating Questionnaire (CoEQ). The CoEQ comprises 21
items designed to assess the intensity and type of food cravings
an individual experiences.8 Recent research has demonstrated
that the CoEQ comprises four subscales: Craving Control, Craving
for Sweet, Craving for Savoury and Positive Mood;20 therefore, a
secondary aim of the current paper was to confirm (using
confirmatory factor analysis (CFA)) this component structure
in an large, independent, treatment-seeking overweight/obese
population.
MATERIALS AND METHODS
Data reported in this paper were pooled from four phase 3 clinical trials
conducted for the Contrave Obesity Research (COR) program (see Table 1).
Only subjects who completed the trials following treatment with 32 mg
naltrexone sustained-release (SR)/360 mg bupropion SR (NB32) or placebo
for 56 weeks were included in the current analysis.
COR program
The COR-I study examined the effect of NB, NB32 (32 mg naltrexone
SR/360 mg bupropion SR) and a lower dose of NB16 (16 mg naltrexone
SR/360 mg bupropion SR) compared with placebo.17 The COR-II study was
similar to the COR-I study and differed only in subjects who did not
maintain at least 5% weight loss were re-randomised to receive either
NB32 or NB48 (48 mg naltrexone SR/360 mg bupropion SR).16 The COR-
BMOD study examined the effect of combining NB32 or placebo with an
intensive behavioural modification program for weight loss.19 Finally, the
COR diabetes mellitus (COR-DM) study examined the effect of NB32 in
patients with type 2 diabetes mellitus.18 In each study the drug or placebo
was administered daily. All subjects provided written informed consent
and the study protocols were approved by each participating institution.
Each study complied with Good Clinical Practice standards and the
Declaration of Helsinki. Only subjects who completed the trials following
treatment with NB32 (32 mg naltrexone SR/360 mg bupropion SR) or
placebo for 56 weeks were included in the current analysis.
Measures
Control of Eating Questionnaire. Subjects completed the CoEQ at baseline
and at weeks 8, 16, 28 and 56 of the interventions. The CoEQ comprises 21
items for which participants are required to respond according to their
experience over the previous seven days. Dalton et al.20 identified an
underlying four-factor structure of the CoEQ with the following subscales:
Craving Control (items 9, 10, 11, 12 and 19), Craving for Sweet (items 3, 13,
14 and 15), Craving for Savoury (items 4, 16, 17 and 18) and Positive Mood
(items 5, 6, 7 and 8). Four items in the CoEQ are not included in the
calculation of the subscales; items 1 and 2 (‘How hungry have you felt?’
and ‘How full have you felt?’, respectively) did not load onto any of the
subscales but were retained in the questionnaire to capture sensations of
general appetite and items 20 and 21 assess an individual’s perceived level
of control over resisting a nominated, craved food item. Twenty items are
assessed using 100-mm visual analogue scales and one item (item 20)
allows participants to enter their own nominated food.
Body weight. Subjects’ body weight was objectively measured using a
calibrated scale, with the subject wearing light clothing and no shoes and
recorded to the nearest 0.1 kg at baseline and every 4 weeks throughout
the 56-week trial period.
Data analysis
Only subjects who completed the trials following treatment with NB32 or
placebo for 56 weeks were included in the current analysis. Those who
received NB16 or NB48 or who did not complete treatment with NB32
were not included in the current analysis. All randomised participants with
baseline measurements and one or more postbaseline measurements
were included in the analysis. Missing data were imputed using the last
observation carried forward. The data were tested to ensure that they met
the requirements for CFA using the Kaiser–Meyer–Olkin measure of
Sampling Adequacy and Bartlett’s test of sphericity. Cronbach’s α was
calculated to evaluate internal consistency. To examine whether initial
changes in Craving Control, Craving for Sweet, Craving for Savoury and
Positive Mood (at week 8) were associated with decreases in BMI over time,
a Conditioned Latent Growth Curve Model was tested. This technique
considers initial levels of the study variable (intercept mean), the inter-
variability in these levels (intercept variance), the average rate at which
participants change (slope mean) and the interindividual variability in that
rate (slope variance).15 Changes in Craving Control, Craving for Sweet,
Craving for Savoury and Positive Mood at week 8 were included in the
model as independent variables. To assess the change (slope) in the
outcome variable (weight loss), the observations from baseline, week 8,
week 16, week 28 and week 56 were used, and hypothesised to decrease
over time. Analyses were conducted using the maximum-likelihood
estimation method. The following indices were used to assess model fit:
χ2; comparative fit index (CFI); Tucker–Lewis index (TLI); root mean square
error of approximation (RMSEA), with 90% confidence intervals; and the
standardised root mean residual (SRMR).21,22 All analyses reported in the
current paper examine the sample as a whole (i.e. NB32 and placebo
combined) as the pattern of results was similar across treatment groups.
However, the effects were stronger in those treated with NB32. To examine
whether early improvements in Craving Control were associated with
weight loss over time, subjects were identified as Craving Control
responders (those with the greatest Craving Control improvement at
week 8) and Craving Control non-responders (those with the lowest
Craving Control improvement at week 8) using a tertile split of change in




The sample included in the current analysis comprised 2073
subjects (79% female) who were randomly assigned to receive
NB32 (n= 1310) or placebo (n= 763) and completed the 56 weeks
of treatment. There were no differences between the treatment
groups with regard to age, sex, race or baseline BMI and weight
(see Table 2), allowing the groups to be combined for this analysis.
Table 1. Overview of the COR program
COR-I COR-II COR-BMOD COR-DM
N (randomised) 1742 1496 793 505
Population BMI 30–45 kg m− 2 or BMI 27–45 kg m−2
with hypertension and/or dyslipidaemia
BMI 27–45 kg m−2 with
type 2 diabetes
Lifestyle intervention Standard Standard Intensive Standard
Duration 56 weeks
Abbreviations: BMI, body mass index; COR, Contrave Obesity Research; COR-BMOD, COR behavioral modification; COR-DM, COR diabetes mellitus; HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Note: Dyslipidaemia, diagnosed with dyslipidaemia, hypercholesterolaemia,
hypertriglyceridaemia, hyperlipidaemia, or low HDL and/or classified due to triglycerides ⩾ 200 mg dl− 1, LDL-C ⩾ 160 mg dl− 1, total cholesterol ⩾ 240 mg dl− 1
or HDL-C o40 mg dl− 1 at baseline; hypertension, diagnosed with hypertension and/or had prescribed antihypertensive medications at baseline.
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Confirmatory factor analysis
Factor analysis was conducted on the CoEQ subjects completed at
baseline. Preliminary analysis of the data revealed that all
assumptions of CFA were met. There was no evidence of
multicollinearity and the Kaiser–Meyer–Olkin measure of Sampling
Adequacy (KMO=0.880) and Bartlett’s test of sphericity
(Χ2(171) = 17 530, Po0.001) indicated that the sample size and
the data were adequate for conducting CFA. CFA was performed
using IBM Amos for Windows (IBM, Chicago, IL, USA; v.22). Fit was
assessed by the CFI, the TLI and the RMSEA. A model with
reasonably good fit can be characterised by values obtained from
the following: a CFI 40.90, a TLI 40.90 and an RMSEA o0.08.23
A four-factor structure was assumed to exist in line with
previous work:20 (1) Craving Control, (2) Craving for Sweet, (3)
Craving for Savoury and (4) Positive Mood. The first four-factor
model, based on Dalton et al.,20 was satisfactory (χ2 (87) = 1503.4,
Po0.001; CFI = 0.92, TLI = 0.90, RMSEA= 0.076); however, the
factor loadings for item 15 ( = 0.15) on the Craving for Sweet
factor and item 16 ( = 0.26) on the Craving for Savoury factor were
too low. Therefore, a second four-factor model was examined with
these items removed. The fit of the second four-factor model was
good and superior to the first four-factor model (χ2 (87) = 952.3,
Po0.001; CFI = 0.95, TLI = 0.94, RMSEA= 0.069) with each item
loading significantly on its respective factor (see Table 3 and
Supplementary Figure S1). As removal of items 15 and 16
improved the model, these items were not included in the final
Craving for Sweet and Craving for Savoury subscale scores.
Based on the outcome of the CFA, CoEQ subscale scores were
calculated as follows: the sum of the items in each subscale was
calculated, and divided by the number of items in the subscale to
obtain a subscale score. For the Positive Mood subscale, item 6
(‘How anxious have you felt?’’) was reversed. For the Craving
Control subscale, the final subscale score was reversed so that a
greater score represented a greater level of Craving Control.
Internal reliability
Regarding internal consistency, the Cronbach’s α values for
Craving Control, Positive Mood, Craving for Savoury and Craving
for Sweet were 0.92, 0.72, 0.78 and 0.85, respectively.
Early change in CoEQ subscales with weight loss at week 56
An unconditional latent growth model estimating weight loss over
time was first conducted. Results indicated a good model fit
(χ2(8) = 589.77, P= o0.001; CFI = 0.97; TLI = 0.97; RMSEA= 0.20 (0.19,
0.22), P= o0.001; SRMR= 0.01). The mean for the intercept factor
was estimated to be 32.97 (Po0.001). The estimate of the mean
for the slope factor was significant (0.37; Po0.001), indicating a
significant decrease of BMI over time. Moreover, there were
significant variance estimates for both the intercept (29.18,
Po0.001) and slope (0.54, Po0.001), which suggested that there
was substantial individual variability around both the mean
starting point of BMI and the mean rate of BMI change over
time. There was a significant estimate for the covariance between
BMI intercept and slope (r=− 0.60), indicating that participants
with higher initial BMI tended to present smaller rates of decrease
in BMI over time. The conditional latent growth model revealed a
good fit (χ2(20) = 686.5, P= 0.000; CFI = 0.97; TLI = 0.95; RMSEA= 0.14
(0.13, 0.15), P= o0.001; SRMR= 0.01). Results indicated that
Craving Control was the only subscale that had a significant
effect on the initial levels of BMI (β=− 0.19; Po0.001). Regarding
the slope of BMI, initial changes in Craving Control were the best
significant predictor (β= 0.17; Po0.001); while initial changes in
Craving Sweet also had a significant effect on the slope of BMI
(β=− 0.07; P= 0.043).
Craving control response and weight loss
Characteristics of the responders and non-responders can be
found in Table 4. There were no differences in baseline measures
of age (t (1257) = 0.109, P= 0.91) or BMI (t (1257) = 1.46, P= 0.16).
The responders had lower body weight (t (1257) = 2.85, Po0.01)
and lower Craving Control scores (t (1257) = 28.8, Po0.001) at
baseline compared with the non-responders. Figure 1 shows
Table 2. Mean (s.d.) subject characteristics for the overall sample
NB32 (n= 1310) Placebo (n= 736)
Age (years) 47.0± 10.8 47.4± 11.1
Sex (% female) 79 79
Race (% white/black/other) 82/14/4 80/16/4
Weight (kg) 101.5± 16.9 100.1± 15.4
BMI (kg m−2) 36.2± 4.4 36.1± 4.2
Abbreviations: BMI, body mass index; NB32, 32 mg naltrexone SR/360 mg
bupropion SR; SR, sustained-release.









Q10. How strong have any food cravings been? 0.88
Q11. How difficult has it been to resist any food cravings? 0.87
Q9. During the last 7 days how often have you had food cravings? 0.85
Q12. How often have you eaten in response to food cravings? 0.83
Q19. Generally, how difficult has it been to control your eating? 0.75
Q8. How contented have you felt? 0.86
Q5. How happy have you felt? 0.73
Q7. How alert have you felt? 0.66
Q6. How anxious have you felt? − 0.40
Q18. How often have you had cravings for savoury foods (fries, crisps, burgers etc.)? 0.94
Q4. How strong was your desire to eat savoury foods? 0.80
Q17. How often have you had cravings for starchy foods (bread, pasta)? 0.53
Q14. How often have you had cravings for other sweet foods (cakes, pastries,
biscuits, etc.)?
0.88
Q3. How strong was your desire to eat sweet foods? 0.82
Q13. How often have you had cravings for chocolate and chocolate flavoured
foods?
0.73
Abbreviation: CoEQ, Control of Eating Questionnaire.
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percentage weight change across the 56-week trial period for
responders and non-responders. There was an interaction
between time point and group (F (3, 3771) = 17.9, Po0.001).
When this was examined, it was revealed that at each time point
responders had a greater percentage weight change compared
with non-responders. The same results were found when
differences in Craving Control response were examined separately
in those treated with NB32 or placebo.
DISCUSSION
The current paper aimed to determine whether early changes in
self-reported control over food craving (i.e. Craving Control) was
associated with weight loss outcomes over 56 weeks in a
combined analysis of four phase 3 clinical trials that examined
the effect of treatment with sustained released combination of NB
or placebo on weight loss in obese adults. The latent growth curve
model demonstrated that early improvements in Craving Control
and reductions in Craving for Sweet throughout the 56-week trial
period were predictive of greater reductions in BMI at the end of
the trial. When subjects were categorised as responders and non-
responders based on their change in Craving Control score at
week 8, individuals identified as non-responders (i.e. those who
had the lowest Craving Control improvement at week 8) lost ~ 3–
4% less weight compared with individuals identified as responders
(i.e. those who had the greatest Craving Control improvement at
week 8). This finding is consistent with previous research that has
shown food craving and increased desire to eat highly palatable
yet restricted foods contribute to poor compliance and adherence
with weight loss interventions.12 In addition, increased wanting
and craving for high-fat sweet foods has been associated with
greater binge and disinhibited eating tendencies and a higher
level of central adiposity in females with overweight and obesity,
indicating that it is a risk factor for weight gain and poor weight
loss outcomes.7,24–26 Promisingly, treatment strategies that target
food cravings have proven to be effective in eliciting greater
weight loss and preventing weight re-gain. For example, previous
research indicates that the use of acceptance-based coping
strategies to manage and resist eating in response to food
cravings is a characteristic of individuals who successfully maintain
their weight loss.11,27,28 Such strategies may prove to be especially
useful for those identified early in an intervention period as
experiencing difficulties with eating in response to food cravings.
Taken together, the findings indicate that food cravings have an
important role in the treatment of obesity and craving for food
presents a target outcome variable for weight loss and prevention
of weight gain. Furthermore, the Craving Control subscale of
the CoEQ may be useful as an early marker to identify those
individuals who may benefit from additional intervention aimed at
improving their control over food cravings, which may result in a
better weight loss (and control over craving) outcome. Although
the contribution of improvements in Craving Control in BMI
change may be considered small (explaining 5% of the variance),
it is important to note that BMI change is likely to be affected by a
large number of individual factors (including genetic, physiologi-
cal, biological, psychological and social factors) that work not only
individually but via interactions to influence the amount of weight
lost. In identifying the factors that are important contributors to
weight loss success, it is possible to further our understanding of
the underlying mechanisms and better support and tailor weight
management strategies. Recently, Smithson and Hill demon-
strated that resisting eating in response food cravings and
reporting greater craving control was predictive of greater weight
change over 7 weeks.21 Similar to the current study, the amount of
variance explained by these factors was 5–7%.
The second aim of the current paper was to determine whether
the previously identified component structure of the CoEQ was
replicable in a treatment-seeking obese sample. CFA in this clinical
population supported a four-factor solution that was coherent
with previous work.20 There were two items in the current analysis,
item 15 ‘How often have you had cravings for fruit or fruit juice?’
on the Craving for Sweet subscale and item 16 ‘How often have
you had cravings for dairy foods (cheese, yoghurt)?’ on the
Craving for Savoury subscale, that did not load significantly onto
their respective factor and were removed from calculation of
these subscales. However, these items have been retained in the
overall CoEQ scale to allow for the analysis of responses on an
item-by-item basis when a specific type of craving is of interest.
Therefore, the subscales can be refined, but the four factors
identified remained as (1) Craving Control, (2) Craving for Sweet,
(3) Craving for Savoury and (4) Positive Mood. The individual
subscales had good internal reliability, and the findings demon-
strated that the subscales, in particular Craving Control, had
predictive validity with regard to weight loss outcomes. These
findings support the use of the CoEQ as a psychometric tool for
Table 4. Mean (s.d.) subject characteristics for the craving control responders and non-responders
Craving control responders (n=629) Craving control non-responders (n= 630)
Age (years) 46.8 (10.3) 46.8 (10.9)
Sex (% female) 84 75
Race (% white/black/other) 81/16/3 86/13/1
Baseline weight (kg)** 99.5 (15.0) 102.1 (17.2)
Week 56 weight (kg)*** 91.1 (16.5) 96.8 (18.7)
Baseline BMI (kg m−2) 36.0 (4.3) 36.3 (4.4)
Week 56 BMI (kg m−2)*** 33.0 (5.1) 34.4 (5.1)
Baseline Craving Control*** 30.6 (13.6) 57.2 (18.8)
Δ Craving Control week 8*** 37.9 (12.7) −7.5 (11.3)
**Po0.01; ***Po0.001.
Figure 1. Percentage weight change across the 56-week trial period
according to Craving Control response for NB32 and placebo
treatment groups combined. ***Po0.001 between craving control
responders and craving control non-responders.
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the measurement of food cravings in research and the pharma-
cological management of obesity.
The primary limitation of the current paper was that while the
sample was large, it was limited with regard to the number of
male participants and the degree of ethnic diversity. This may
restrict the generalisability of the findings. However, the outcomes
of the current integrated analysis suggest that the CoEQ is a valid
measure of the experience of food cravings, and offers a useful
research and clinical contribution to the field in that it samples
food craving experiences over a 7-day period, assesses aspects of
mood and distinguishes specific, directional cravings from loss of
control over eating due to cravings. Food cravings are common
experiences but are key in the development of overweight and
obesity, weight re-gain and the maintenance of poor eating
habits. Treatment and prevention strategies would benefit from
identifying individuals who frequently experience intense food
cravings and (over)eat in response to them as they may be more
susceptible to weight gain and less successful in their attempts to
manage their weight. In future research, the CoEQ will provide the
means for psychometrically robust outcome measures in clinical
trials on obesity and weight management.
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